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Skin and soft tissue infections (SSTIs) encompass a variety of pathological conditions ranging from simple superficial
infections to severe necrotizing soft tissue infections. Necrotizing soft tissue infections (NSTIs) are potentially
life-threatening infections of any layer of the soft tissue compartment associated with widespread necrosis and
systemic toxicity. Successful management of NSTIs involves prompt recognition, timely surgical debridement or
drainage, resuscitation and appropriate antibiotic therapy. A worldwide international panel of experts developed
evidence-based guidelines for management of soft tissue infections. The multifaceted nature of these infections has
led to a collaboration among surgeons, intensive care and infectious diseases specialists, who have shared these
guidelines, implementing clinical practice recommendations.Executive summary
Skin and soft tissue infections (SSTIs) encompass a var-
iety of pathological conditions involving the skin and
underlying subcutaneous tissue, fascia, or muscle and
ranging from simple superficial infections to severe nec-
rotizing infections that may involve the dermal, subcuta-
neous, fascia, and muscle layers [1].
SSTIs may affect any part of the body, although the
lower extremities, the perineum, and the abdominal wall
are the most common sites of involvement. SSTIs are a
relatively infrequent clinical problem; however, surgeons
are often called upon for their management.
These guidelines focus mainly on necrotizing soft tis-
sue infections (NSTIs). The mortality resulting from* Correspondence: massimosartelli@gmail.com
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unless otherwise stated.NSTIs appears to have decreased over the past decade,
possibly due to improved recognition and earlier delivery
of more effective therapy [2].
Successful management of NSTIs involves prompt rec-
ognition, timely surgical debridement or drainage, ag-
gressive resuscitation and appropriate antibiotic therapy.
A worldwide international panel of experts developed
evidenced-based guidelines for management of soft tis-
sue infections. The guidelines outline clinical recom-
mendations based on the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE)
hierarchy criteria summarized in Table 1 [3,4].Surgical site infections
1) Surgical site infections require prompt and wide
opening of the surgical incision. Antimicrobial therapy
is recommended for deep incisional surgical site in-
fections if systemic signs of sepsis are present, if sourceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Grading of recommendations from Guyatt and colleagues [3,4]
Grade of
recommendation
Clarity of risk/benefit Quality of supporting evidence Implications
1A
Strong
recommendation,
high-quality evidence
Benefits clearly outweigh risk and
burdens, or vice versa
RCTs without important limitations or
overwhelming evidence from observational
studies
Strong recommendation, applies to
most patients in most
circumstances without reservation
1B
Strong
recommendation,
moderate-quality
evidence
Benefits clearly outweigh risk and
burdens, or vice versa
RCTs with important limitations (inconsistent
results, methodological flaws, indirect analyses or
imprecise conclusions) or exceptionally strong
evidence from observational studies
Strong recommendation, applies to
most patients in most
circumstances without reservation
1C
Strong
recommendation,
low-quality or very
low-quality evidence
Benefits clearly outweigh risk and
burdens, or vice versa
Observational studies or case series Strong recommendation but
subject to change when higher
quality evidence becomes available
2A
Weak
recommendation,
high-quality evidence
Benefits closely balanced with risks
and burden
RCTs without important limitations or
overwhelming evidence from observational
studies
Weak recommendation, best action
may differ depending on the
patient, treatment circumstances,
or social values
2B
Weak
recommendation,
moderate-quality
evidence
Benefits closely balanced with risks
and burden
RCTs with important limitations (inconsistent
results, methodological flaws, indirect or
imprecise) or exceptionally strong evidence from
observational studies
Weak recommendation, best action
may differ depending on the
patient, treatment circumstances,
or social values
2C
Weak
recommendation,
Low-quality or very
low-quality evidence
Uncertainty in the estimates of
benefits, risks, and burden; benefits,
risk, and burden may be closely
balanced
Observational studies or case series Very weak recommendation;
alternative treatments may be
equally reasonable and merit
consideration
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(Recommendation 1 C).
2) In patients who have had clean operations, anti-
microbial therapy should cover gram-positive organisms;
in contrast, in patients who have had procedures on the
gastrointestinal or genitourinary tract antimicrobial ther-
apy should cover both gram-positive and gram-negative
organisms (Recommendation 1 C).
Non necrotizing superficial soft tissue infections
3) Erysipelas, and cellulitis are managed by antimicrobial
therapy against Gram-positive bacteria (Recommendation
1 C).
4) Lack of clinical response for cellulitis may be due to
resistant strains of staphylococcus or streptococcus, or
deeper processes, such as necrotizing fasciitis or myone-
crosis (Recommendation 1 C).
5) Therapy for community-acquired MRSA should be
recommended for patients at risk for CA-MRSA or who
do not respond to beta-lactam therapy within 48 to
72 hours (Recommendation 1 C).
6) If a streptococcal toxic shock syndrome is sus-
pected, an antiribosomal agent such as clindamycin orlinezolid can be used to reduce exotoxin and superanti-
gen production (Recommendation 1 C).
Simple abscesses
7) Incision and drainage is the primary treatment for
simple abscesses or boils. Antibiotics are not needed
(Recommendation 1 C).
Complex abscesses
8) Complex skin and subcutaneous abscesses are typic-
ally well circumscribed and respond to incision and
drainage. Antimicrobial therapy is required if systemic
signs of sepsis are present, in immunocompromised
patients, if source control is incomplete or for the ab-
scesses with significant cellulitis (Recommendation 1 C).
9) Empiric antibiotic therapy should be directed toward
the likely pathogens involved.
Therapy for community-acquired MRSA should be
recommended for patients at risk for CA-MRSA
(Recommendation 1 C).
10) Inadequate resolution should prompt consider-
ation of further drainage, resistant pathogens, or host
immune failure (Recommendation 1 C).
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11) A rapidly progressive soft tissue infection should be
always treated aggressively as a necrotizing soft tissue in-
fection (Recommendation 1 C)
12) Both CT and MRI may be useful for diagnosing nec-
rotizing soft tissue infections. However MRI may be difficult
to perform under emergency situations. (Recommendation
2 C).
13) In unstable patients, ultrasound may be useful to
differentiate simple cellulitis from necrotizing fasciitis
(Recommendation 2 C).
Management of patients with necrotizing soft tissue
infections
14) Patients with severe sepsis or septic shock caused by
NSTI require early source control, antimicrobial therapy,
and supportive treatment (Recommendation 1 C).
Source control in patients with necrotizing soft tissue
infections
15) Surgical source control must be early and aggressive
to halt progression of the inflammatory process caused
by NSTI (Recommendation 1 C).
Hyperbaric oxygen in patients with necrotizing soft tissue
infections
16) Although the benefit of adjuvant hyperbaric oxygen
(HBO) therapy remains controversial, it may be consid-
ered where it is available (Recommendation 2 C).
Antimicrobial therapy in patients with necrotizing soft
tissue infections
17) Early appropriate empiric coverage against suspected
pathogens should be initiated, based upon the clinical
setting for patients with NSTI (Recommendation 1 C).
18) Patients whose clinical setting or gram stain suggests
rapidly progressive infection potentiated by exotoxins
from Gram positive pathogens (S. pyogenes, CA-
MRSA, Clostridial species), treatment with antimicrobial
agents should be combined with antiribosomal agents
(clindamycin or linezolid). Patients who present with rap-
idly progressive infections with gram stains of tissue dem-
onstrating gram negative pathogens (Aeromonas sp.,
Eikenella, Vibrio sp) should be treated with antiribosomal
agents targeting gram negative pathogens (tetracyclines)
(Recommendation 1 C).
19) Appropriate empiric coverage against MRSA
should be immediately initiated in patients with NSTI
(Recommendation 1 C).
20) Since it is impossible to exclude with certainty a
polymicrobial necrotizing infection, an aggressive broad-
spectrum empiric antimicrobial therapy should initially
be selected to cover gram-positive, gram-negative, andanaerobic organisms until culture-specific results and
sensitivities are available (Recommendation 1 C).
21) An appropriate de-escalation of antimicrobial ther-
apy is suggested once culture results come back (Recom-
mendation 1 C).
Supportive treatment in patients with necrotizing soft
tissue infections
22) Supportive treatment in managing NSTI must be
early and aggressive to halt progression of the inflamma-
tory process (Recommendation 1 A).
Intravenous immunoglobulins in patients with necrotizing
soft tissue infections
23) Intravenous immunoglobulins may be considered in
all patients with NSTI and evidence of organ dysfunc-
tion (Recommendation 2 C).
Early nutritional support in patients with necrotizing soft
tissue infections
24) Early nutritional support should be established
(Recommendation 2 C).
Classification
Several systems of classification have been used to de-
scribe SSTIs. In 1998 The US Food and Drug Administra-
tion (FDA) classified SSTIs into two broad categories -
uncomplicated and complicated - for the purpose of
clinical trials evaluating new antimicrobials for the treat-
ment of SSTIs. Uncomplicated SSTIs included superfi-
cial infections such as cellulitis, simple abscesses,
impetigo, and furuncles that either require antibiotics
alone or in conjunction with surgical incision for drain-
age of abscess. In contrast, complicated SSTIs involve
the deep soft tissues and require significant surgical
intervention [5].
The terms “complicated” and “uncomplicated” skin
structure infections is still valid and can be useful in de-
scribing SSTIs [6].
Uncomplicated SSTIs are at low risk for life- or limb-
threatening infection unless they are not properly
treated. Patients who have uncomplicated SSTIs can be
treated with either empiric antibiotic therapy according
to likely pathogen and local resistance patterns or simple
surgical drainage.
The practice guidelines of the Infectious Diseases Society
of America (IDSA) [7] for the diagnosis and management
of skin and soft tissue infections classifies SSTIs into
five categories: 1) superficial uncomplicated infection
(includes impetigo, erysipelas and cellulitis), 2) necro-
tizing infections, 3) infections associated with bites
and animal contact, 4) surgical site infections and 5) in-
fections in the immunocompromised host.
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of local and systemic signs and the presence or absence
of comorbid conditions for patients presenting as out-
patients to guide the clinical management, treatment,
and admission decisions for patients with SSTIs. This
system is organized into classes of infection:
Class 1: patients with SSTI, but no signs or symptoms
of systemic toxicity or co-morbidities.
Class 2: patients are either systemically unwell with
stable co-morbidities or are systemically well, but have a
comorbidity (e.g. diabetes, obesity) that may complicate
or delay resolution.
Class 3: patients appear toxic and unwell (fever, tachy-
cardia, tachypnea and/or hypotension).
Class 4: patients have sepsis syndrome and life-
threatening infection, for example necrotizing fasciitis.
SSTIs may be also classified according to the anatom-
ical tissue layers involved [9].
Superficial infections are located at the epidermal and
dermal layers, while cellulitis may extend into the sub-
cutaneous tissue. Deep infections extend below the der-
mis and may involve the subcutaneous tissue, fascial
planes or muscular compartments and present as com-
plex abscesses, fasciitis, or myonecrosis.
SSTIs may also be classified as non-necrotizing or nec-
rotizing soft tissue infections [10]. Non-necrotizing, com-
plicated soft tissue infections typically involve one or both
of the superficial layers of the skin (epidermis and dermis)
and the subcutaneous tissue, such as complex abscesses,
but may occasionally involve deeper structures.
NSTI is an inclusive term intended to describe all in-
fections with a necrotizing component involving any or
all the layers of the soft tissue compartment, from the
superficial dermis and subcutaneous tissue to the deeper
fascia and muscle [11].
NSTIs most commonly involve the muscular fascial
layers and warrant prompt, aggressive surgical debride-
ment [6].
NSTIs have also been sub-classified according to the
type and number of pathogens initiating the infectious
process [12]:
Type 1: polymicrobial infections that typically arise
from a chronic, indolent source and spread along fascial
planes. This type of infection comprises roughly 85-90%
of NSTIs; Type 2: monomicrobial gram positive, aerobic
cocci, either Streptococcus species or community-
acquired methicillin resistant Staphylococcus aureus
(CA-MRSA). Its ill effects are related to both toxin pro-
duction and rapid growth rate of pathogens. These infec-
tions comprise about 10-15% of NSTIs; and Type 3:
monomicrobial infections initiated by a variety of viru-
lent gram positive or gram negative bacilli such as Clos-
tridia, Vibrio, Aeromonas, Eikenella, or Bacillus species.
These are the most uncommon of NSTIs.World Society of Emergency Surgery classification
Treatment decisions for SSTI depend on numerous fac-
tors including the severity and depth of infection and
the clinical setting.
The WSES expert panel classified soft tissue infections
using the classification system illustrated below.
Surgical Site infections
Incisional
– Superficial
– Deep
Non-necrotizing SSTIs
Superficial infections (Impetigo, erysipelas, cellulitis)
Simple abscess, boils and carbuncles
Complex abscesses
Necrotizing SSTIs (NSTIs)
Necrotizing cellulitis
Necrotizing fasciitis
Fournier’s gangrene
Necrotizing myositis
The first group includes surgical site infections (SSIs).
Soft tissue non-surgical site infections are divided into
non-necrotizing and necrotizing soft tissue infections.
Surgical site infections
SSIs represent a separate chapter among the soft tissue
infections [13]. They are post-operative infections and
because of their multifaceted aspects they are framed
into a separate group.
The Center for Disease Control and Prevention (CDC)
defined criteria for classification of surgical site infec-
tions. SSIs are classified as: superficial incisional infec-
tion, deep incisional infection, and organ space infection.
Superficial incisional infections are the most common
type of surgical site infections [14]. Organ space infec-
tions are not soft tissue infections.
The development of an SSI depends on contamination
of the wound site at the end of a surgical procedure and
specifically relates to the pathogenicity and inoculum of
microorganisms present, balanced against the host’s im-
mune response.
Numerous patient-related (endogenous) and process/
procedures related (exogenous) risk factors for develop-
ing an SSI have been described [15].
Some factors, such as age and gender, are obviously
not amenable to changes or improvements. However,
addressing other potential factors, such as the nutritional
status, smoking, proper use of antibiotics and accurate
intraoperative technique, can reduce the likelihood of
SSI.
Prophylactic antibiotic administration is an established
approach for reducing the risk of SSIs in various fields
of elective surgery [16,17].
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Non-necrotizing soft tissue infections include superficial
infections, complex abscesses, and infections developing
in damaged skin (animal and human bites). If untreated,
these can evolve into necrotizing infections.
Superficial infections
Superficial infections encompass either superficial spread-
ing infection and inflammation within the epidermis and
dermis that may be treated with antibiotics alone or a well
circumscribed abscess that may be treated by drainage
alone.
Physical examination usually reveals erythema, tender-
ness, and induration. The majority of superficial skin
and soft tissue infections are caused by gram positive
bacteria, particularly streptococci and S. aureus. Three
common presentations consist of impetigo, erysipelas,
and cellulitis. They are managed by antimicrobial ther-
apy against Gram-positive bacteria.
Impetigo is a skin infection that is common through-
out the world. It is characterized by discrete purulent le-
sions nearly always caused by β-haemolytic streptococci
and/or S. aureus.
Erysipelas is a fiery red, tender, painful plaque with well-
demarcated edges and is commonly caused by streptococ-
cal species, usually S. pyogenes. S. aureus rarely causes
erysipelas [18].
Cellulitis is an acute bacterial infection of the dermis
and the subcutaneous tissue that most commonly affects
the lower extremities, although it can affect other areas.
It causes local signs of inflammation, such as warmth,
erythema, pain, lymphangitis, and frequently systemic
upset with fever and raised white blood cell count [19].
For a simple superficial abscess or boil, incision and
drainage is the primary treatment, and antibiotics are not
needed [20,21]. To be considered a simple abscess, indur-
ation and erythema should be limited only to a defined
area of the abscess and should not extend beyond its bor-
ders. Additionally, simple abscesses should not have ex-
tension into deeper tissues or multiloculated extension.
Complex abscesses
Common sites of origin may be perineal or perianal infec-
tions, perirectal abscesses, diabetic foot or lower-extremity
ulcerations, traumatic injuries, chronic cutaneous cysts,
intravenous drug injection sites, gastrointestinal pathology
with perforation, genitourinary pathology, animal bites,
and pressure ulcers.
Complicated skin and subcutaneous abscesses are typ-
ically well circumscribed and respond to incision and
drainage with adjuvant antibiotic therapy.
The cornerstone of treatment is early surgical drainage.
Antimicrobial therapy is required perioperatively if sys-
temic signs of sepsis are present, in immunocompromisedpatients, if source control is incomplete or for the ab-
scesses with significant cellulitis. The initiating pathogens
often differ according to the originating site. Aerobic
gram-positive pathogens are isolated in most complicated
abscesses. Depending on the origin, anaerobes, Enterobac-
teriaceae, and Clostridium spp. may also be present [1].
Although most cases can be managed by incision and
drainage, abscesses in injecting drug users (IDUs) require
special considerations as compared to soft tissue infec-
tions which are not caused by intravenous drug abuse
[22-25]. There are two main sources of organisms: the
IDUs themselves (their oropharynx, skin or faeces), and
the environment. Contamination may occur when the
user prepares or injects the drug, uses shared needles or
re-uses injection paraphernalia. Manufacturing and
handling of injectable drugs may be far from hygienic
[26]. Persistent signs of sepsis require evaluation for the
presence of endocarditis. Foreign bodies, such as broken
needles, should be ruled out by radiography, and duplex
sonography should be performed to identify the presence
of vascular complications [27]. A broad-spectrum anti-
biotic effective against aerobic and anaerobic organisms
should be administered in patients with these infections.
Infections developing in damaged skin
It is a heterogeneous group that includes soft tissue infec-
tions developing in damaged skin such as bite wounds
(animal and human bites), burn wounds or in pressure or
vascular ulcers. If managed incorrectly, these infections
can develop into more complicated soft tissue infections
Soft tissue infection is the most common complication
of animal and human bites [28-30]. The risk of infection
depends on the type of bite, the site of injury, the time
elapsed from the bite until presentation, host factors,
and the management of the wound.
Antibiotic prophylaxis is always recommended for
high-risk wounds. For patients with signs of sepsis, com-
promised immune status, severe comorbidities, associated
severe cellulitis, severe and deep wounds, a broad-
spectrum antibiotic effective against aerobic and anaer-
obic organisms is always required.
Patients with serious burn injury require immediate
care. Significant burn injuries can predispose to infec-
tious complications. Burn wound infections are one of
the most important and potentially serious complica-
tions that occur in the acute period following injury.
Accurate medications of the wound with early excision
of the eschar can substantially decrease the incidence of
invasive burn wound infection.
Although burn wound surfaces are sterile immediately
following thermal injury, these wounds may be colonized
with microorganisms. If the patient's host defenses and
therapeutic measures (such as excision of necrotic tissue
and wound medications) are inadequate, microorganisms
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can occur.
Burn wound infections usually are polymicrobial. They
can be immediately colonized by gram-positive bacteria
from the patient's endogenous skin flora or the external
environment. However they can also be rapidly colo-
nized by gram-negative bacteria, usually within a week
of the burn injury.
Pressure ulcers are localized areas of tissue necrosis
that tend to develop when soft tissue is compressed be-
tween a bony prominence and an external surface for a
prolonged period of time. The damage may be relatively
minor, or it may lead to massive destruction of deeper
tissues. The majority of pressure ulcers develop in areas
adjacent to the ischium, sacrum, and greater trochanter.
Combination of surgical and antimicrobial interven-
tions may be required to manage infected decubitus
ulcers. Surgical debridement is necessary to remove
necrotic tissue. Antimicrobial therapy should be used
for patients with severe pressure ulcer infections, in-
cluding those with spreading cellulitis or patients with
signs of sepsis. Because such infections usually are
polymicrobial, therapeutic regimens should be directed
against both gram-positive and gram-negative faculta-
tive organisms as well as anaerobic organisms.
In many cases a correct wound care management can
largely prevent the appearance of these infections.
Necrotizing soft tissue infections
NSTIs include necrotizing cellulitis, necrotizing fasciitis,
Fournier’s gangrene and necrotizing myositis. They are
life-threatening, invasive, soft tissue infections caused by
aggressive, usually gas-forming bacteria. Delay in diag-
nosing and treating these infections increases the risk of
mortality.
NSTIs may involve dermal and subcutaneous compo-
nents (necrotizing cellulitis), fascial component (necrotiz-
ing fasciitis), and muscular components (necrotizing
myositis) either singularly or in combination. NSTIs may
also be classified into three types defined by the bacterial
pathogens initiating the infection and their typical clinical
characteristics; type 1 – poly-microbial, type 2 – mono-
microbial pathogenic β-haemolytic Streptococci or CA-
MRSA, type 3 – mono-microbial secondary to a variety of
pathogenic bacilli. In the early phases, necrotizing soft tis-
sue infections, cause localized inflammatory reactions in
the involved tissues. Necrosis occurs because of direct cel-
lular injury from bacterial endo/exotoxins [31], significant
inflammatory oedema [32] within a closed tissue compart-
ment, thrombosis of local blood vessels, and tissue ische-
mia. Circulating toxins may cause systemic illness [33]
which can progress to septic shock, multisystem organ
dysfunction, and death [34]. Patients with NSTIs due to
either Staphylococcus aureus or group A Streptococcus(Streptococcus pyogenes) may develop toxic shock
syndrome (TSS). TSS is a toxin-mediated acute life-
threatening illness, where the systemically absorbed toxins
act as super antigens, massively activating the host inflam-
matory response.
Necrotizing cellulitis
Necrotizing cellulitis is similar to non-necrotizing cellu-
litis in bacterial aetiology and pathogenesis but is more
serious and may be rapidly progressive and accompanied
by significant systemic inflammatory changes (toxic
shock syndrome). The pathogenesis and severity of these
infections are related to the particular pathogenicity of
the strains of either β-haemolytic streptococci or CA-
MRSA. In the presence of tissue necrosis, other bacteria
may become secondarily involved, particularly anaerobes.
Necrotizing fasciitis
Necrotizing fasciitis (NF) is a NSTI involving the fascial
planes overlying the muscle. Due to the tenuous blood
and lymphatic supply of the fascia and the potential
planes on either surface, infectious processes can spread
rapidly and relatively unimpeded once initiated. Thus,
NF comprises a spectrum of diseases characterized by
extensive, rapidly progressive necrosis involving the
fascia and peri-fascial planes and may secondarily in-
volve the surrounding subcutaneous tissue, skin, and
muscle [35].
NF is most often poly-microbial and synergistic in na-
ture with the specific bacteria involved being related to
the etiologic source or body region of origin.
This condition can involve any part of body but primarily
involves extremities, abdomen or perineum. Anaya et al. in
a study of 150 cases of necrotizing fasciitis reported that
extremities were the most common site of infection (58%)
followed by the abdomen and perineum [36].
Usually necrotizing fasciitis is precipitated by some
form of injury or local pathological condition: blunt or
penetrating trauma, surgical site infection, burns, ulcers,
abscess and even child birth have been documented as
precipitating factors for NF. Improperly treated superfi-
cial infections can progress to NF. Body piercing proce-
dures and tattooing, very minor trauma such as abrasion
and insect bites have also been found to be able to initiate
NF. In some situations NF has arisen without an identifi-
able previous trauma or pathological condition [37].
The mortality associated with the disease is high and
has been reported from 6% to as high as 76% [38]
Fournier’s gangrene
Fournier’s gangrene is a rapidly progressive, variant of
necrotizing fasciitis involving the external genitalia and
perineum. Due to the complexity of fascial planes, this
infection may extend up to the abdominal wall, down
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occasionally, into the retroperitoneum.
It has a mortality rate that reaches the 20–50% in
many contemporary series [39,40].
Fournier’s gangrene is nearly universally poly-microbial
in origin, and is often caused by aerobic and anaerobic
gram positive and gram negative bacteria. The origin of
the infection is identifiable in the majority of cases and is
predominantly from anorectal, genito-urinary or local cu-
taneous sources [41].
Iatrogenic factors leading to Fournier's gangrene have
been reported after injection sclerotherapy and banding
of haemorrhoids, haemorrhoidectomy and stapled hae-
morrhoidopexy [42].
Diagnosis is based on clinical signs and physical exam-
ination. Imaging may be needed to confirm clinical suspi-
cions and to help in identifying the extent of the soft
tissue involvement, particularly in the peri-rectal and
retroperitoneal planes.
Fournier’s Gangrene Severity Index (FGSI) is a standard
score for predicting outcome in patients with Fournier
gangrene and is obtained from a combination of physio-
logical parameters at admission including temperature,
heart rate, respiration rate, sodium, potassium, creatinine,
leukocytes, haematocrit and bicarbonate. A FGSI score
above 9 has been demonstrated to be sensitive and specific
as a mortality predictor in patients with Fournier’s gan-
grene [43].
Necrotizing myositis
Necrotizing myositis is a rare NSTI that is a serious,
life-threatening infection of the muscle with local and
systemic complications [6]. These infections can pro-
gress rapidly due to the virulence of the etiologic
pathogens.
Like other NSTIs, early and appropriate antimicro-
bial and surgical debridement are the cornerstones of
management.
Healthy muscle tissue is usually quite resistant to infec-
tious processes. However, muscle can become infected
by specific virulent pathogens with significant exotoxin
production or when muscle perfusion and viability are
compromised. Necrotizing myositis and myonecrosis of
healthy muscle may occur secondary to a variety of
clostridial species and, less commonly, to virulent Strep.
pyogenes. In these cases, the pathogenicity is believed to
be related to exotoxins promoting thrombosis and break
down healthy muscle. Both infections can arise spontan-
eously or secondary to injury or adjacent infection.
Myositis may also occur in muscle sites that have
been compromised by injury, ischemia, malignancy or
surgery. The predominant pathogens are S aureus, in-
cluding community-associated MRSA, group A strepto-
cocci, gram-negative aerobic and facultative bacilli [44].Presenting findings are localized pain in a single muscle
group, muscle spasm, and fever.
Principles of treatment
Antimicrobial therapy
The principal barrier against microbial invasion is the
skin. It constantly interacts with the external environ-
ment and is colonized with different populations of bac-
teria. Intact and well vascularized skin is highly resistant
to bacterial invasion.
The majority of SSTIs involving healthy skin are caused
by aerobic Gram-positive cocci, specifically S. aureus and
streptococci. Strains of S. aureus and Group A β-
haemolytic streptococci (GAS) can produce a variety of
toxins that may both potentiate their virulence and affect
the soft tissues and allow invasion of the dermis [45].
Polymicrobial infections occur when aerobic Gram
negative and anaerobes invade soft tissues.
SSTIs management has recently become more compli-
cated because of the increasing prevalence of multidrug-
resistant pathogens.
For SSTIs that develop following significant antibiotic
exposure or in hospitals or other healthcare settings, the
increasing resistance among both Gram-positive and
Gram-negative bacteria makes empirical treatment regi-
mens challenging.
Considerable variation in the resistance rates of S. aur-
eus to methicillin (or oxacillin) has been noted between
continents, with the highest rates in North America
(35.9%), followed by Latin America (29.4%) and Europe
(22.8%) [46].
Although MRSA has been usually acquired during
exposure in hospitals and other healthcare facilities (HA-
MRSA), there has been a recent increase in MRSA infec-
tions presenting in the community (CA-MRSA) [47].
CA-MRSA strains are genetically and phenotypically
distinct from HA-MRSA. They may be susceptible to a
wider range of anti-staphylococcal antimicrobials (some
are resistant only to β-lactams). Populations at increased
risk for CA-MRSA are listed below [47]:
Children <2 years old
Athletes (mainly contact-sport participants)
Injection drug users
Men who have sex with men
Military personnel
Inmates of correctional facilities, residential homes or
shelters
Vets, pet owners and pig farmers
Patients with post-flu-like illness and/or severe
pneumonia
Patients with concurrent SSTI
History of colonization or recent infection with
CA-MRSA
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particularly quinolones or macrolides
CA-MRSA infections are becoming increasingly com-
mon. They can have a rapid and devastating course and
may produce the pathogenic Panton–Valentine leucoci-
din toxin (PVL), which destroys white blood cells and is
an important virulence factor [48,49].
Antibiotics recommended for CA-MRSA infections
are listed below.
Outpatient treatment:
Minocycline100 mg q12h
or
Trimethoprim and Sulfamethoxazole 160/800 mg
q12h
or
Doxycycline 100 mg q12h
or
Clindamycin 300–600 mg q8h
or
Linezolid 600 mg q12h
Inpatient treatment:
Vancomycin 15 mg/kg IV q12h
or
Teicoplanin LD 12 mg/kg IVq h12h for 3 doses then
6 mg/kg q12 h
or
Tigecycline 100 mg IV as a single dose; then 50 mg
IV q12h
or
Linezolid 600 mg q12h
or
Daptomycin 4–6 mg/kg q24h
For empirical coverage of CA-MRSA in outpatients
with SSTI, oral antibiotic options include clindamycin,
trimethoprim-sulfamethoxazole (TMP-SMX), a tetracyc-
line (doxycycline or minocycline), and linezolid. If cover-
age for both β-hemolytic streptococci and CA-MRSA is
required, options include clindamycin alone or TMP-
SMX or a tetracycline in association with a β-lactam (eg,
amoxicillin) or linezolid alone [50].
For hospitalized patients with severe SSTI, in addition
to surgical debridement and broad-spectrum antibiotics,
empirical therapy for MRSA should be considered, pend-
ing culture data. Options include intravenous (IV) vanco-
mycin, PO or IV linezolid 600 mg twice daily, daptomycin
4 mg/kg/dose IV once daily, clindamycin 600 mg IV or
PO 3 times a day [50], tigecycline 100 mg IV LD, then
50 mg twice daily.
Glycopeptides have been for many years the micro-
biological agents of choice for difficult Gram positive
infections. Fortunately, staphylococcal resistance toglycopeptides remains rare, although rising minimal
inhibitory concentrations (MICs) of glycopeptides may
affect the efficacy of these antibiotics [51,52].
Increased resistance to glycopeptides has encouraged
the development of new agents active against Gram-
positive bacteria, particularly for severe soft tissue infec-
tions where an aggressive antimicrobial management is
always recommended, such as linezolid [53-55], tigecyc-
line [56,57] and daptomycin [58,59].
Linezolid has been considered an agent of choice in
complicated skin and soft-tissue infections (cSSTIs), It
has the advantages of early intravenous-to-oral switch
with the oral preparation having very high bioavailability
and excellent tissue penetration [53,54].
In 2010 an open-label study compared oral or intra-
venous linezolid with intravenous vancomycin for treat-
ment of cSSTIs caused by MRSA.
Patients receiving linezolid had a significantly shorter
length of stay and duration of intravenous therapy than
patients receiving vancomycin. Both agents were well
tolerated. Adverse events were similar to each drug's
established safety profile [54].
Recently a Cochrane meta-analysis including all rando-
mised controlled trials (RCTs) comparing linezolid with
vancomycin in the treatment of SSTIs [55].
Linezolid was associated with a significantly better
clinical (RR 1.09, 95% CI 1.03 to 1.16) and microbio-
logical cure rate in adults (RR 1.08, 95% CI 1.01 to 1.16).
For those infections due to MRSA, linezolid was signifi-
cantly more effective than vancomycin in clinical (RR
1.09, 95% CI 1.03 to 1.17) and microbiological cure rates
(RR 1.17, 95% CI 1.04 to 1.32).
The daily cost of outpatient therapy was less with oral
linezolid than with intravenous vancomycin. Although in-
patient treatment with linezolid cost more than inpatient
treatment with vancomycin per day, the median length of
hospital stay was three days shorter with linezolid [55].
Tigecycline has a broader range of activity, covering
infections caused not only by resistant Gram-positive
bacteria but also by many resistant Gram-negative or-
ganisms including those producing extended spectrum
β-lactamases. It is only available as an intravenous for-
mulation [56].
An interesting study evaluated the penetration of tige-
cycline into soft tissues in patients with cSSTIs requiring
surgical intervention was published in 2011.
Tissue and blood samples were obtained one to six
days (mean 2.5 days) after initiation of tigecycline treat-
ment. The authors found higher concentrations of tige-
cycline in soft tissue than in the serum at the same time
point [57].
Daptomycin has proven efficacy in patients with Gram-
positive cSSTIs, including those caused by Staphylococ-
cus aureus resistant to Methicillin [58].
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concentrations in skin and soft tissues. In 2010 a meta-
analysis compared effectiveness and toxicity of daptomy-
cin with that of other antimicrobials for the treatment of
SSTIs. Four studies were included in the analysis (3 were
randomized RCTs). Vancomycin and semisynthetic peni-
cillins were used in the comparator arm. Three studies
reported on patients with cSSTIs. Daptomycin tissue
penetration supports its use in the treatment of cSSTIs
and it has been shown to be non-inferior to vancomycin
and semi-synthetic penicillins [59].
Broad-spectrum antimicrobial therapy should be initi-
ated as soon as possible. In a study of 492 patients with
community-onset MRSA SSTIs, 95% of episodes treated
with an active antibiotic within 48 hours were treated
successfully, compared with an 87% rate of successful
treatment in patients who did not receive an active anti-
biotic. After logistic regression analysis, failure to initiate
active antimicrobial therapy within 48 hours of presenta-
tion was the only independent predictor of treatment
failure (adjusted odds ratio [OR], 2.80; 95% CI, 1.26 to
6.22) [60].
Using data from more than 100 hospitals in the United
States, Berger et al. [61] recently published a retrospect-
ive analysis of all adults hospitalized for complicated
skin and skin-structure infections over a 9-year period.
The authors defined "initial therapy" as all parenteral
antibiotics administered <24 hours of admission, and
such therapy was assumed to have failed if the patient
(1) received new antibiotic (s) subsequently (excluding
similar/narrower spectrum antibiotics or those begun at
discharge), or (2) underwent drainage/debridement/am-
putation >72 h after admission.
Initial treatment failure in patients hospitalized for
complicated skin and skin-structure infections was asso-
ciated with significantly worse clinical outcomes, longer
hospital stays, and higher hospital charges than with suc-
cessful initial treatment.
Source control
Source control represents a key component of success in
the management of sepsis [62].
Source control for SSTIs includes drainage of infected
fluids, debridement of infected soft tissues, removal of
infected devices or foreign bodies. It should also include
definite measures to correct any anatomic derangement
resulting in ongoing microbial contamination and restor-
ing optimal function [5]. Delay in source control for pa-
tients with NSTIs has been repeatedly associated with a
greater mortality.
Supportive treatment for the critically ill patients
NSTIs can present with a fulminant course and may be
associated with great morbidity and high case-fatalityrates, especially when they occur in conjunction with
toxic shock syndrome.
Aggressive treatment of the underlying organ dysfunc-
tion is an essential component of improving patient out-
come. Physiologic support including close invasive
monitoring in an intensive care unit setting and aggres-
sive resuscitation are often necessary in necrotizing
infections.Soft tissue infections in immunocompromised patients
SSTIs in immunocompromised patients can be challen-
ging as they can be caused by unusual microorganisms.
SSTIs in immunocompromised patients may progress
rapidly, then becoming life threatening and are more dif-
ficult to eradicate with antibiotics alone, in the absence
of an intact immune system [63]. Additionally, fungal
SSTI infections are more common in immunocomprom-
ised populations.
There are few studies on immunocompromised pa-
tients with soft-tissue infections.
A single-institution retrospective cohort study evaluat-
ing immunocompromised patients with necrotizing soft
tissue infections was recently published [63].
In this study immunodeficiency was defined by cortico-
steroid use, active malignancy, receiving chemotherapy or
radiation therapy, diagnosis of human immunodeficiency
virus or AIDS, or prior solid organ or bone marrow trans-
plantation with receipt of chronic immunosuppression.
Immunocompromised patients with NSTIs were asso-
ciated with delays in diagnosis and surgical treatment
and with higher in-hospital mortality. At presentation,
immunocompromised patients failed to exhibit typical
clinical and laboratory signs of NSTIs. The authors con-
cluded that physicians caring for such patient popula-
tions should maintain a higher level of suspicion for
necrotizing soft tissue infections and consider early sur-
gical evaluation and treatment.Recommendations
Surgical site infections
1) Surgical site infections require prompt and wide
opening of the surgical incision. Antimicrobial ther-
apy is recommended for deep incisional surgical site
infections if systemic signs of sepsis are present, if
source control is incomplete or in immunocomprom-
ised patients (Recommendation 1 C).
2) In patients who have had clean operations,
antimicrobial therapy should cover gram-positive
organisms; in contrast, in patients who have had
procedures on the gastrointestinal or genitourinary
tract antimicrobial therapy should cover both gram-
positive and gram-negative organisms (Recommendation
1 C).
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organisms.
The pathogens isolated from infections differ, primarily
depending on the type of surgical procedure. In clean
surgical procedures, in which the gastrointestinal, gyne-
cologic, and respiratory tracts have not been entered,
Staphylococcus aureus from the exogenous environment
or the patient's skin flora is the usual cause of infection.
In other categories of surgical procedures, including
clean-contaminated, contaminated, and dirty, the polymi-
crobial aerobic and anaerobic flora closely resembling the
normal endogenous microflora of the surgically resected
organ are the most frequently isolated pathogens [4].
Treatment involves widely opening the incision. Anti-
microbial therapy is required in deep infections if systemic
signs of toxicity are present, if source control is incomplete
or in immunocompromised patients. Broad-spectrum em-
piric antimicrobial therapy should initially be selected to
cover potentially resistant pathogens. Cultures should be
always obtained and antimicrobial therapy modified based
on the culture and sensitivity results.
Non necrotizing superficial infections
3) Erysipelas, and cellulitis are managed by antimicro-
bial therapy against Gram-positive bacteria (Recom-
mendation 1 C).
4) Lack of clinical response for cellulitis may be due
to resistant strains of staphylococcus or streptococ-
cus, or deeper processes, such as necrotizing fasciitis
or myonecrosis (Recommendation 1 C).
5) Therapy for community-acquired MRSA should
be recommended for patients at risk for CA-MRSA or
who do not respond to beta-lactam therapy within 48
to 72 hours (Recommendation 1 C).
6) If a streptococcal toxic shock syndrome is sus-
pected, an antiribosomal agent such as clindamycin
or linezolid can be used to reduce exotoxin and super-
antigen production (Recommendation 1 C).
The term “non-necrotizing cellulitis” has been used to
incorporate two entities, erysipelas and cellulitis, which
are diffusely spreading skin infections not associated with
suppurative foci.
However, a fine distinction exists between erysipelas
and cellulitis. Erysipelas has a clear line of demarcation
between involved and uninvolved tissue and lesions
raised above the surrounding normal skin [64].
Cellulitis involves deeper layers of the dermis and sub-
cutaneous tissue and has less distinctive features than
erysipelas [64].
They are commonly caused by streptococcal species,
usually b-hemolytic streptococci (usually group A). S.
Aureus rarely causes erysipelas and cellulitis [64], but
such infections usually are more suppurative and less
diffuse.Superficial, non-necrotizing infections caused by cer-
tain strains of Group A-streptococcal (GAS) may be as-
sociated with streptococcal toxic shock syndrome,
characterized by rapid progression of septic shock and
organ failure [65].
As previously discussed, the recent dramatic increase
in CA-MRSA makes the empiric treatment of staphylo-
coccal infections troubling.
Diagnostic studies have a low yield in patients with
superficial soft tissue infections and usually do not help
with the diagnosis. However, establishing whether cellu-
litis represents signs of a deeper and/or more severe
infectious process can be difficult but is of considerable
importance as the majority of NSTIs are originally diag-
nosed as cellulitis.
Lack of clinical response could be due to unusual or-
ganisms, resistant strains of staphylococcus or strepto-
coccus, or deeper processes, such as necrotizing fasciitis.
In patients who become increasingly ill, deeper infec-
tions should be always suspected.
For these infections, a penicillinase-resistant penicillin
is the drug of choice.
Moxifloxacin or Levofloxacin may be suggested in pa-
tients who are allergic to beta-lactams. Clindamycin re-
duces exotoxin and superantigen production by pathogenic
strains of GAS, and can be used in association as an adjunct
in the treatment of streptococcal TSS [66].
Therapy for community-acquired MRSA should be
added for patients at risk for CA-MRSA and subse-
quently for patients who do not respond to beta-lactam
therapy within 48 to 72 hours or who have chills, fever, a
new abscess, increasing erythema, or uncontrolled pain
[67].
Although in cellulitis, swabs and aspirates of the lead-
ing edge of the site of infection have a low yield of
around 10% [68], when it is possible, antibiotic treatment
should be modified, on the basis of antimicrobial suscep-
tibilities of organisms obtained.
Simple abscesses
7) Incision and drainage is the primary treatment for
a simple abscesses or boils. Antibiotics are not
needed (Recommendation 1 C).
For a simple superficial abscess or boil, incision and
drainage is the primary treatment, and antibiotics are not
needed [21,22]. Simple abscesses should not have exten-
sion into deeper tissues or multiloculated extension.
Complex abscesses
8) Complex skin and subcutaneous abscesses are typ-
ically well circumscribed and respond to incision and
drainage. Antimicrobial therapy is required if sys-
temic signs of sepsis are present, in immunocom-
promised patients, if source control is incomplete or
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mendation 1 C).
9) Empiric antibiotic therapy should be directed
toward the likely pathogens involved.
Therapy for community-acquired MRSA should be
recommended for patients at risk for CA-MRSA
(Recommendation 1 C).
10) Inadequate resolution should prompt consider-
ation of further drainage, resistant pathogens, or host
immune failure (Recommendation 1 C).
The cornerstone of treatment is early surgical drain-
age. Antimicrobial therapy is required if systemic signs
of sepsis are present, in immunocompromised patients,
if source control is incomplete or for the abscesses with
significant cellulitis.
Complicated abscesses may involve a variety of patho-
gens. Aerobic gram-positive pathogens are isolated in
most complicated abscesses. They may involve only a sin-
gle pathogen but are frequently poly-microbial in origin
and may involve a number of organisms [69].
Empiric antibiotic therapy should be directed toward
the likely pathogens involved. Broad-spectrum agents
with coverage of gram-positive, gram-negative, and an-
aerobic pathogens may be required depending on the
clinical setting. Given the high frequency of MRSA, this
pathogen should be empirically covered [1] if it is sus-
pected, but no randomized studies are available for the
treatment of SSTI specifically caused by CA-MRSA.
Diagnosis of necrotizing soft tissue infections
11) A rapidly progressive soft tissue infection should
be always treated aggressively as a necrotizing soft
tissue infection (Recommendation 1 C).
Initially, distinguishing between cellulitis and a necrotiz-
ing soft tissue infection that requires operative interven-
tion may be difficult. Most cases of necrotizing soft tissue
infection are originally diagnosed as cellulitis. However,
since time to operative debridement is a strong determin-
ant of outcome in NSTIs, timely diagnosis is essential.
Patients with necrotizing soft tissue infections usually
present with severe pain that is out of proportion to the
physical findings.
Necrotizing infections more commonly present with
systemic signs of sepsis than non-necrotizing infections,
although TSS from both S. aureus and Strep. pyogenes
can occur without a necrotizing process. Physical find-
ings of necrotizing soft tissue infections may include ten-
derness beyond the area of erythema, crepitus, and
cellulitis that is refractory to antimicrobial therapy.
A rapidly progressive soft tissue infection should be ini-
tially treated as a necrotizing infection. Bullous changes,
ecchymotic changes of the skin, and loss of skin sensa-
tion should all be considered as a necrotizing infection.
Crepitus is most commonly the result of gas withintissues. While the presence of crepitus and gas within
tissues is highly suggestive of a NSTI, its absence does
not rule out its presence. All bacteria growing under aer-
obic conditions produce CO2 as a by-product and the
free diffusion of CO2 typically limits gas collection in
these cases, thus explaining the absence of gas in rapidly
progress S. pyogenes infections.
The clinical picture may worsen very quickly, some-
times during a few hours.
Delay in diagnosis and/or treatment correlates with a
poor outcome, leading to severe sepsis and/or multiple
organ failure and only early surgical debridement and
appropriate antimicrobial treatment can prevent sepsis
progression and death.
In order to predict the presence of necrotizing soft tis-
sue infection, a group of investigators described the devel-
opment and application of the Laboratory Risk Indicator
for Necrotizing infection (LRINEC) score in a 2004 report.
This scoring system assigned points for abnormalities in
six independent variables: serum C-reactive protein level
(>150 mg/L), WBC count (>15,000/μL), hemoglobin level
(<13.5 g/dL), serum sodium level (<135 mmol/L), serum
creatinine level (>1.6 mg/dL), and serum glucose level
(>180 mg/dL). With a score of 8 or higher, there is a 75%
risk of a necrotizing soft tissue infection. The authors rec-
ommended that the LRINEC score be used to determine
which patients require further diagnostic testing, given
that the negative predictive value of this screening tool
was 96% [70]. Subsequent evaluation of the LRINEC score
has demonstrated that it lacks the sensitivity to be a useful
adjunct for the diagnosis of necrotizing infections.
The diagnosis of NSTIs is primarily a clinical diagnosis.
However, plain radiographs, ultrasound, computed tom-
ography (CT), magnetic resonance imaging (MRI), may
be able to provide useful information for necrotizing in-
fection when the diagnosis is uncertain [71].
The most common plain radiographic findings are simi-
lar to those of cellulitis, with increased soft-tissue thick-
ness and opacity. Frequently, plain radiographs are normal
unless the infection and necrosis are advanced. The char-
acteristic finding is gas in the soft tissues, but subcutane-
ous gas may be present in few cases of necrotizing
infection [72] and is not present in pure aerobic infections
such as those caused by S. pyogenes.
Additionally, subcutaneous gas may not be present in
earlier stages of the disease process and only become
manifest as the patient’s condition deteriorates.
12) Both CT and MRI may be useful for diagnosing
necrotizing soft tissue infections. However MRI may
be difficult to perform under emergency situations.
(Recommendation 2 C).
13) In unstable patients ultrasound may be useful
to differentiate simple cellulitis from necrotizing fas-
ciitis (Recommendation 2 C).
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than plain radiography in identifying early necrotizing
fasciitis. Findings consistent with necrotizing fasciitis are
fat stranding, fluid and gas collections that dissect along
fascial planes, and gas in the involved soft tissues. Add-
itionally, fascial thickening and non-enhancing fascia on
contrast CT suggests fascial necrosis [73].
In 2010 a case series study [74] about CT for the diag-
nosis of necrotizing soft tissue infections was published.
Of 67 patients with study inclusion criteria, 58 under-
went surgical exploration, and necrotizing soft tissue
infection was confirmed in 25 (43%). The remaining 42
patients had either non-necrotizing infections during sur-
gical exploration (n = 33) or were treated non-operatively
with successful resolution of the symptoms (n = 9). The
sensitivity of CT to identify NSTI was 100%, specificity
was 81%, positive predictive value was 76%, and negative
predictive value was 100%.
Magnetic resonance imaging has been the imaging mo-
dality of choice for necrotizing fasciitis. The patients with
NF have usually a significantly greater frequency of the
following MR findings: thick (≥3 mm) abnormal signal in-
tensity on fat-suppressed T2-weighted images, low signal
intensity in the deep fascia on fat-suppressed T2-weighted
images, a focal or diffuse non-enhancing portion in the
area of abnormal signal intensity in the deep fascia, exten-
sive involvement of the deep fascia, and involvement of
three or more compartments in one extremity [75].
Schmid et al. found MRI to be 100% sensitive and 86%
specific and have a diagnostic accuracy of 94% for diag-
nosing necrotizing fasciitis. However, the authors noted
that MRI imaging tends to overestimate the extent of
deep fascial involvement. Therefore, treatment should be
based on a combination of clinical findings and MRI re-
sults [76].
Ultrasound has the advantage of being rapidly per-
formed at bedside and may be helpful in differentiating
simple cellulitis from necrotizing fasciitis. In a prospect-
ive observational study of 62 patients with clinically sus-
pected necrotizing fasciitis, ultrasound had a sensitivity
of 88.2%, specificity of 93.3%, positive predictive value of
95.4%, negative predictive value of 95.4%, and diagnostic
accuracy of 91.9%. The authors considered the findings
of diffuse subcutaneous thickening accompanied with
fluid accumulation of >4 mm in depth along the deep
fascial layer predictive of necrotizing fasciitis [77].
Fascial biopsy with frozen section has been suggested
as a means to achieve earlier diagnosis of NSTIs [78,79].
However frozen biopsy is not very practical and requires
availability and experience from the pathologists, and
the time taken to carry out and analyze the sample could
be used for debridement [80].
The Finger test is another adjunct method described for
diagnosing NSTIs. It is performed under local anesthesia.A 2-cm incision is made down to the deep fascia. A min-
imal tissue resistance to finger dissection (positive Finger
test), the absence of bleeding, presence of necrotic tissue,
and/or murky and grayish (“dishwater”) fluid following in-
cision, all may support the diagnosis of NSTI [81].
Management of necrotizing soft tissue infections
14) Patients with severe sepsis or septic shock caused
by NSTI require early source control, antimicrobial
therapy, and supportive treatment (Recommendation
1 C).
Source control of necrotizing soft tissue infections
15) Surgical source control must be early and aggres-
sive to halt progression of the inflammatory process
caused by NSTI (Recommendation 1 C).
The most critical factors for reducing mortality from
necrotizing soft tissue infections are early recognition
and urgent operative debridement [82].
Surgical debridement must be aggressive to halt pro-
gression of infection. Cultures of infected fluid and tis-
sues should be obtained during the initial surgical
debridement and the results used to tailor specific
antibiotic management.
Radical surgical debridement of the entire affected area
should be performed, continuing the debridement into
the healthy-looking tissue.
In the setting of Fournier’s gangrene, diverting colostomy
has been demonstrated to improve the outcome and the
need for fecal diversion depends upon severity of the dis-
ease. It helps in decreasing sepsis by minimizing bacterial
load in the perineal wound thus controlling infection [83].
Diverting colostomy does not eliminate the necessity
of multiple debridements, nor reduces the number of
these procedures [84].
Recently rectal diversion devices have been marketed.
They are silicone catheters designed to divert fecal mat-
ter in patients with diarrhea, local burns, or skin ulcers.
The devices protect the wounds from fecal contamin-
ation and reduce in the same way a colostomy does,
both the risk of skin breakdown and repeated inocula-
tion with colonic microbial flora. Estrada et al. showed
that it was effective way for fecal diversion and forms an
alternative to colostomy [85].
Postoperative wound care starts with meticulous
haemostasis. Non-adherent compressive dressings should
be applied, followed by repeat wound inspection in ≤
24 hours [86].
Any patient with extensive necrosis or who is consid-
ered to have not be adequately debrided at the initial
operation should be returned to the operating room in
24–48 hours for a second look [5].
Further debridement should be repeated until the in-
fection is controlled.
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vacuum-assisted wound closure (VAC) therapy for
managing patients who have acute NSTI demonstrating
that VAC technique of wound closure is effective in
managing non-healing limb wounds consequential to
surgical treatment for patients suffering from acute
necrotizing fasciitis [87-89]. Negative pressure therap-
ies should be reserved for use only after adequate
source control has been obtained.Hyperbaric oxygen therapy
16) Although the benefit of adjuvant hyperbaric oxygen
(HBO) therapy remains controversial, it may be consid-
ered where it is available (Recommendation 2 C).
The role of hyperbaric oxygen (HBO) as an adjunctive
treatment is still controversial, and no prospective ran-
domized clinical trials have been published. There is very
little evidence supporting the benefits of hyperbaric oxy-
gen therapy in treating NSTI.
In 2009, a retrospective review investigating the effect
of HBO in treating NSTI was published [90].
Adjunctive use of HBO to treat necrotizing soft
tissue infections did not reduce the mortality rate,
number of debridements, hospital length of stay, or
duration of antibiotic use.
In order to determine the effect of hyperbaric oxygen
HBO therapy on mortality, complication rate, discharge
status/location, hospital length of stay and inflation-
adjusted hospitalisation cost in patients with NSTIs a
retrospective study of 45,913 patients in the Nationwide
Inpatient Sample from 1988 to 2009 was published in 2012
[91]. This retrospective analysis of HBO therapy in NSTI
showed that despite the higher hospitalisation cost and
longer length of stay, the statistically significant reduction
in mortality supports the use of HBO therapy in NSTI.
Recently a review about HBO therapy for treating
acute surgical and traumatic wounds was published [92].
The authors concluded that there is a lack of high qual-
ity, valid research evidence regarding the effects of HBO
therapy on wound healing.
Although there is a trend in clinical outcomes which
shows that HBO therapy may be useful in managing
NSTI [93], the benefit of adjuvant HBO therapy for
NSTI remains controversial, and more robust evidence
by prospective randomized trials is necessary. HBO ther-
apy should always be considered as an adjunct treatment
and should never replace surgical debridement.
The expert panel supports the use of HBO therapy in
those hospitals where the hyperbaric chamber is available.Antimicrobial therapy
17) Early appropriate empiric coverage against sus-
pected pathogens should be initiated, based uponthe clinical setting for patients with NSTI (Recom-
mendation 1 C).
18) Patients whose clinical setting or gram stain sug-
gests rapidly progressive infection potentiated by
exotoxins from Gram positive pathogens (S. pyogenes,
CA-MRSA, Clostridial species), treatment with anti-
microbial agents should be combined with antiriboso-
mal agents (clindamycin or linezolid). Patients who
present with rapidly progressive infections with gram
stains of tissue demonstrating gram negative pathogens
(Aeromonas sp., Eikenella, Vibrio sp) should be treated
with antiribosomal agents targeting gram negative
pathogens (tetracyclines) (Recommendation 1 C).
19) Appropriate empiric coverage against MRSA
should be immediately initiated in patients with nec-
rotizing soft tissue infection (Recommendation 1 C).
20) Since it is impossible to exclude with certainty a
polymicrobial necrotizing infection, an aggressive
broad-spectrum empiric antimicrobial therapy should
initially be selected to cover gram-positive, gram-
negative, and anaerobic organisms until culture-specific
results and sensitivities are available (Recommendation
1 C).
21) An appropriate de-escalation of antimicrobial
therapy is suggested once culture results return (Rec-
ommendation 1 C).
Microbiologically, NSTIs have been classified as either
type 1 (polymicrobial) or type 2 (mono-microbial) or type
3 (mono-microbial infections initiated by a variety of
virulent gram positive or gram negative bacilli such as
Clostridia, Vibrio, Aeromonas, Eikenella, and Bacillus
species) [80,94,95]. Occasionally in immunocompromised
patients NSTIs may be also caused by mycotic species.
Polymicrobial infections are more common, with cul-
tures yielding a mixture of aerobic and anaerobic organ-
isms. These infections typically occur in the perineum
and trunk.
NF is associated with surgical procedures involving the
bowel [96] or penetrating abdominal trauma, decubitus
ulcer, perianal abscess, the site of injection in intravenous
drug users, and spread from a perineal or vulvo-vaginal
infection [6]. The etiologic isolates consist of Gram-
positive organisms, such as Staphylococcus aureus, S.
pyogenes, and enterococci; Gram-negative aerobes, such
as Escherichia coli; and anaerobic organisms, such as
Bacteroides or Clostridia species.
Mono-microbial infections are less common than the
poly-microbial variety. These typically occur in the limbs
and afflict healthy patients with no implicative comor-
bidities. There may be often a history of trauma, fre-
quently trivial.
As S. pyogenes and S. aureus and Group A Strepto-
coccus are the usual pathogens [97], selection of specific
antimicrobials that inhibit toxin production by may be
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of toxic shock syndrome [98].
An acceptable empiric antimicrobial regimen should
always include antibiotics, which covers CA-MRSA with
the additional benefit of inhibiting invasive group A
Streptococcus virulence proteins.
Selection of antibiotics that inhibit toxin production
may be helpful, particularly in those patients who have
evidence of toxic shock syndrome, potentially present in
patients who have streptococcal and staphylococcal in-
fections. Protein cytotoxins play an important role in the
pathogenesis of various staphylococcal infections, and
toxin production should be considered when selecting
an antimicrobial agent for gram-positive pathogens [99].
Linezolid and clindamycin plays an important role be-
cause it may significantly reduce the early release of exo-
toxins from Gram positive pathogens [99,100].
Since it is impossible to exclude with certainty a poly-
microbial infection, an aggressive broad-spectrum em-
piric antimicrobial therapy should initially be selected to
cover gram-positive, gram-negative, and anaerobic or-
ganisms until culture-specific results and sensitivities are
available.
Empiric antimicrobial therapy should be started as
soon as possible.
Subsequent modification (de-escalation) of the initial
regimen becomes possible later, when culture results are
available and clinical status can be better assessed, 24–72
hours after initiation of empiric therapy.
In Appendix 1 antimicrobial regimens for necrotizing
soft tissue infections are listed.
Supportive treatment
22) Supportive treatment in managing NSTI must be
early and aggressive to halt progression of the in-
flammatory process (Recommendation 1 A).
Early detection of severe sepsis and prompt aggressive
treatment of the underlying organ dysfunction is an essen-
tial component of improving outcome of critical ill patients.
Deep soft tissue infections may present with a fulmin-
ant course and may be associated with great morbidity
and high case-fatality rates, especially when they occur
in conjunction with toxic shock syndrome.
After initial debridement, and early antimicrobial ther-
apy, patients require early intensive care for haemo-
dynamic and metabolic support. Patients may loss fluids,
proteins and electrolytes from a large surgical wound
[101]. In addition hypotension is caused by vasodilation
induced by the systemic inflammatory response syn-
drome to infection [102].
Fluid resuscitation and analgesia are the mainstays of
support for patients with advanced sepsis usually com-
bined with vasoactive amines associated with mechanic
ventilation.These patients often exhibit extensive extracellular fluid
sequestration within the affected area, as well as more
generalized sequestration resulting from sepsis. The ad-
equacy of intravascular volume repletion is assessed by
mean arterial pressure (MAP) >65 mm Hg, central venous
pressure (CVP) of 8–12 mmHg in combination with a
central venous oxygen saturation (ScvO2) > 70% and
Urine output >0.5 mL/kg/hr [103].
It has been established that the general prognostic value
of a lactate of 4 mM/L on hospital admission is important;
multiple studies have confirmed the risk stratification of
this lactate level for illness severity and mortality in both
the pre-hospital and in-hospital setting [104-108]. Lactate
clearance has also been associated with decreased mortal-
ity in patients with severe sepsis and septic shock [109].
The absence of clear benefits following the administra-
tion of colloid solutions compared to crystalloid [110],
supports a high-grade recommendation for the use of
crystalloid solutions in the initial resuscitation of patients
with severe sepsis and septic shock [103].
In patients whose hypotension does not resolve with
appropriate intravascular fluid resuscitation, vasopressor
agents are useful for raising blood pressure, improving
myocardial function, and increasing organ and tissue per-
fusion [103].
Intravenous immunoglobulins
23) Intravenous immunoglobulins may be considered
in all patients with NSTI and evidence of organ dys-
function (Recommendation 2 C).
The use of intravenous immunoglobulin for treating
necrotizing soft tissue infections remains controversial,
but is based on a potential benefit related to binding of
gram-positive organism exotoxins [111].
Intravenous immunoglobulin therapy has been advo-
cated for NSTI caused by streptococci and staphylo-
cocci. Intravenous immunoglobulin provides antibodies
that can neutralize circulating exotoxins produced by
these organisms and may modulate the systemic inflam-
matory response induced by cytokine stimulation [112].
Expert panel supports the use of early immunoglobu-
lins in all the patients with NSTI associated to severe
sepsis and septic shock.
Nutritional support in patients with necrotizing soft tissue
infection
24) Early nutritional support should be established
(Recommendation 2C).
Adequate nutritional support improves outcomes [113].
The best and simple assessment of prior nutritional state
is a detailed history of prior illness and nutritional intake
combined with clinical examination of fat and muscle dis-
tribution. The enormous endocrine and cytokine burst of
systemic inflammatory response common to necrotizing
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requirements. Currently recommendations suggest that
25 kcal/kg/day is a reasonable target intake for ICU pa-
tients initially for the first week however it may be inad-
equate in the long run and a target of 30 or 35 kcal/kg/
day [114-116].
There are no data showing improvement in relevant
outcome parameters using early enteral nutrition (EN)
in necrotizing soft tissue infection patients.
Parenteral nutrition (PN) should be reserved for pa-
tients in whom EN is contraindicated or is unlikely to
meet nutritional requirements within 4 to 5 days.
Appendix 1
Antimicrobial therapy for necrotizing soft tissue
infections
Necrotizing fasciitis
Linezolid 600 mg bid
+
Piperacillin/tazobactam 4/0-5 g LD infused in 30’ then
16/2 g qd by CI
Or
Daptomycin 6 mg/kg qd
+
Piperacillin/tazobactam 4/0-5 g LD infused in 30’ then
16/2 g qd by CI
+
Clindamycin 600–900 mg qid
Fournier’s gangrene
If signs and symptoms of severe sepsis are not present
Piperacillin/tazobactam 4/0-5 g LD infused in 30’ then
16/2 g qd by CI
+
Clindamycin 600–900 mg qid
If signs and symptoms of severe sepsis are present
Meropenem 1 g LD infused in 30’ then 1 g qid by ex-
tended infusion (3 to 6 h)
+
Linezolid 600 mg bid
Necrotizing cellulitis
If signs and symptoms of severe sepsis are not present
Amoxicillin/Clavulanate 2/0.2 gm qid IV
+
Clindamycin 600 mg qid IV
If signs and symptoms of severe sepsis are present
Linezolid 600 mg bid
+
Piperacillin/tazobactam 4/0-5 g LD infused in 30’ then
16/2 g qd by CI
Or
Daptomycin 6 mg/kg qd
+Piperacillin/tazobactam 4/0-5 g LD infused in 30’ then
16/2 g qd by CI
+
Clindamycin 600–900 mg qid
Necrotizing myositis
If signs and symptoms of severe sepsis are not present
Amoxicillin/Clavulanate 2/0.2gm qid IV
+
Clindamycin 600 mg qid IV
If signs and symptoms of severe sepsis are present
Linezolid 600 mg bid
+
Piperacillin/tazobactam 4/0-5 g LD infused in 30’ then
16/2 g qd by CI
Or
Daptomycin 6 mg/kg qd
+
Piperacillin/tazobactam 4/0-5 g LD infused in 30’ then
16/2 g qd by CI
+
Clindamycin 600–900 mg qid
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